Next Day Disclosure Return (Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares)

Equity issuer						St	atus:	N	ew Submi	ssion	
Alphamab Oncology											
14 October 2025											
Ordinary shares	Ty	ype of shares	Not applicable			Listed on the Exchange		ige Y	Yes		
09966	De	Description Ordinary shares			•			'			
res or treasury shares											
Events			Changes in issued shares (excluding treasury shares)		Changes in treasury shares						
			Number of issued shares (excluding treasury shares)			er of treasury		• .	•	Total number of issued shares	
Opening balance as at (Note 1) 13 October 2025		971,087,697					3,060,000			974,147,697	
Repurchase of shares (shares held as treasury shares)		-293,000		0.0302 %	293		HKD 13.5389		13.5389		
ctober 2025											
	Alphamab Oncology 14 October 2025 In the state of the s	Alphamab Oncology 14 October 2025 and by a listed issuer where there has been a Stock Exchange of Hong Kong Limited (2.7). Ordinary shares Ty 09966 Description Events 13 October 2025 es held as treasury shares)	Alphamab Oncology 14 October 2025 ad by a listed issuer where there has been a change in its issue a Stock Exchange of Hong Kong Limited (the "Exchange") (the "Exchange") (the "Exchange") Ordinary shares Openits Type of shares Description Change (excluding treasury shares) 13 October 2025 971,08 es held as treasury shares)	Alphamab Oncology 14 October 2025 ad by a listed issuer where there has been a change in its issued so a Stock Exchange of Hong Kong Limited (the "Exchange") (the "Mes"). Ordinary shares Type of shares Not agree or treasury shares Changes in is (excluding treasury shares) Number of issued shares (excluding treasury shares) 13 October 2025 971,087,697 es held as treasury shares) -293,000	Alphamab Oncology 14 October 2025 If d by a listed issuer where there has been a change in its issued shares or treasury shares a Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or restrict. Ordinary shares Type of shares Not applicable Operation Ordinary shares Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) 13 October 2025 971,087,697 es held as treasury shares) -293,000 0.0302 %	Alphamab Oncology 14 October 2025 Ind by a listed issuer where there has been a change in its issued shares or treasury shares which is a Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27 (iii). Ordinary shares Type of shares Not applicable Operation Ordinary shares Changes in issued shares (excluding treasury shares) Pumber of issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) 13 October 2025 Sheld as treasury shares) -293,000 0.0302 %	Alphamab Oncology 14 October 2025 Ind by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable as Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules stock Exchange of the Rules stock	Alphamab Oncology 14 October 2025 Ind by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant of Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governes"). Ordinary shares Type of shares Not applicable Listed on the Exchange of Honges in issued shares (excluding treasury shares) Changes in issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) 13 October 2025 971,087,697 3,060,000 13 October 2025 Se held as treasury shares) -293,000 0,0302 % 293,000 HKD	Alphamab Oncology 14 October 2025 25 Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the List"). Ordinary shares Type of shares Not applicable Description Ordinary shares Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) 13 October 2025 Page 10 Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the List of	Alphamab Oncology 14 October 2025 2d by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Step Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Step Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Step Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Step Stock Exchange of Stares or treasury shares Type of shares or treasury shares Changes in issued shares (excluding treasury shares) Changes in issued shares (excluding treasury shares) As a % of existing an	

Page 1 of 5 v 1.3.0

ConfirmationNot applicable

Notes to Section I:

- 1. Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
- 2. Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
- 3. The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
- 4. In the case of a share repurchase or redemption, the "issue/ selling price per share" shall be construed as "repurchase price per share" or "redemption price per share".
 - Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
- 5. The closing balance date is the date of the last relevant event being disclosed.
- 6. For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled.
 - If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
- 7. Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
- 8. "Identical" means in this context:
 - the securities are of the same nominal value with the same amount called up or paid up;
 - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.

Page 2 of 5 v 1.3.0

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).

Repurchase report

Кери	irchase report									
Section	on II									
1. Cla	. Class of shares Ordinary shares		-	Type of shares	Not applicable	Not applicable Listed on the Exchange		nge	Yes	
Stock code (if listed) 09966		ı	Description	Ordinary shares						
A.	Repurchase rep	oort			•					
	Trading date	Number of shares repurchased		d of repurchase (Note 1)	Repurchase price per highest repurchase p share \$		Lowest repurchase price per share \$		Aggregate price paid \$	
1).	14 October 2025	293,000	On the Exchange		HKD	13.83 H	KD 1	.3.03 HKD	3,966,90	
	number of shares rchased	293,000					Aggregate price pa	aid \$HKD	3,966,900	
repur	ber of shares rchased for ellation	0	-							
repur	ber of shares rchased for holding easury shares	293,000	_							
В.	Additional info	rmation for issuer who ha	as a prima	ry listing on the	e Exchange					
1).	Date of the resolu	ution granting the repurchas	se mandate	•					12 June 2025	
2).	Total number of	shares which the issuer is a	uthorised t	o repurchase und	der the repurchase man	date			96,218,980	
3).	Number of shares repurchased on the Exchange or another stock exchange under the repurchase mandate (a)						401,000			
4).		er of issued shares (excluding to a specific of issued shares (excluding t							0.0417 %	
5).	Moratorium perio	od for any issue of new shar	es, or sale	or transfer of trea	asury shares after the s	hare repurc	hase(s) set out in Part A	Up to	13 November 2025	

We hereby confirm that the repurchases made on the Exchange set out in Part A above were made in accordance with the Main Board Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated May 21, 2025 which has been filed with the Exchange.

Page 3 of 5 v 1.3.0

Notes to Section II:

- 1. Please state whether the repurchase was made on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.
- 2. Subject to the carve-out set out in Main Board Rule 10.06(3)(a)/ GEM Rule 13.12, an issuer may not (i) make a new issue of shares, or a sale or transfer of any treasury shares; or (ii) announce a proposed new issue of shares, or a sale or transfer of any treasury shares, for a period of 30 days after any purchase by it of shares, whether on the Exchange or otherwise, without the prior approval of the Exchange.

Page 4 of 5 v 1.3.0

Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.

Report of on-market sale of treasury shares

Not applicable

Submitted by:	XU Ting							
•	(Name)							
T:41	Executive Director							
	(Director, Secretary or other Duly Authorised Officer)							

Page 5 of 5 v 1.3.0